COLL vs. VKTX, AXSM, KRYS, TGTX, OGN, SRRK, ALVO, RARE, ADMA, and BHVN
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), TG Therapeutics (TGTX), Organon & Co. (OGN), Scholar Rock (SRRK), Alvotech (ALVO), Ultragenyx Pharmaceutical (RARE), ADMA Biologics (ADMA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.
Collegium Pharmaceutical vs.
Collegium Pharmaceutical (NASDAQ:COLL) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
Collegium Pharmaceutical has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
In the previous week, Viking Therapeutics had 3 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 11 mentions for Viking Therapeutics and 8 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.73 beat Viking Therapeutics' score of 0.39 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.
Collegium Pharmaceutical currently has a consensus price target of $43.80, indicating a potential upside of 31.33%. Viking Therapeutics has a consensus price target of $106.75, indicating a potential upside of 226.95%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Collegium Pharmaceutical.
Collegium Pharmaceutical has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
76.0% of Viking Therapeutics shares are owned by institutional investors. 4.0% of Collegium Pharmaceutical shares are owned by insiders. Comparatively, 4.7% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Viking Therapeutics received 234 more outperform votes than Collegium Pharmaceutical when rated by MarketBeat users. Likewise, 79.92% of users gave Viking Therapeutics an outperform vote while only 65.37% of users gave Collegium Pharmaceutical an outperform vote.
Collegium Pharmaceutical has a net margin of 14.78% compared to Viking Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 104.67% beat Viking Therapeutics' return on equity.
Summary
Viking Therapeutics beats Collegium Pharmaceutical on 10 of the 18 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:COLL) was last updated on 1/18/2025 by MarketBeat.com Staff
Free COLL Stock Alerts